1385PDA randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. (23rd October 2018) - Peters, S; Danson, S J; Hasan, B; Reinmuth, N; Majem, M; Tournoy, K G; Mark, M T; Pless, M; Cobo, M; Rodriguez-Abreu, D; Falchero, L; Massutí, B; et al.